Jeremy Pearlman

Jeffrey Cohen

- STRATA Skin Sciences, Inc. announced a registered direct offering of **1,097,547 shares** of common stock at a purchase price of **$2.204 per share**.  **[1051514_0001213900-25-083709_ea025575601ex99-1_strata.htm:0]** **[1051514_0001213900-25-083709_ea0255756-8k_strata.htm:1]** 
- The offering is expected to generate approximately **$2.42 million** in gross proceeds, which the company intends to use for **working capital and general corporate purposes**.  **[1051514_0001213900-25-083709_ea025575601ex99-1_strata.htm:0]** **[1051514_0001213900-25-083709_ea0255756-8k_strata.htm:1]** 
- The closing of the offering is anticipated to occur on or about **September 4, 2025**, with Ladenburg Thalmann & Co. Inc. acting as the exclusive placement agent and receiving a **7.0% cash fee** of the gross proceeds plus up to **$50,000** in expense reimbursement.  **[1051514_0001213900-25-083709_ea025575601ex99-1_strata.htm:0]** **[1051514_0001213900-25-083709_ea0255756-8k_strata.htm:1]**

STRATA Skin Sciences Announces Pricing of Registered Direct Offering

- STRATA Skin Sciences (SSKN) announced its patent portfolio provides **intellectual property and market exclusivity** for combination therapies using its XTRAC excimer laser with JAK inhibitor, Systemic, and Biologic drugs.  **[1051514_cfc8f3888cf7498ea5aee260c906b7a1_0]** 
- The company holds **three key granted patents** (WO2021053673A1, US20220305282A1, US20220296919A1) that establish intellectual property rights for these combination therapies, which are expected to become standard of care for difficult-to-treat conditions.  **[1051514_cfc8f3888cf7498ea5aee260c906b7a1_0]** 
- These patents support expansion into new indications for inflammatory and autoimmune skin conditions, such as **vitiligo, atopic dermatitis, and alopecia areata**, in addition to psoriasis.  **[1051514_cfc8f3888cf7498ea5aee260c906b7a1_0]** **[1051514_cfc8f3888cf7498ea5aee260c906b7a1_1]** 
- The American Medical Association's CPT Editorial Panel approved updates to codes 96920–96922, expanding reimbursement eligibility for XTRAC treatments to these new conditions, effective **January 1, 2027**.  **[1051514_cfc8f3888cf7498ea5aee260c906b7a1_1]**  STRATA aims to secure temporary CMS codes for reimbursement as early as the **2026 rule cycle**, potentially **tripling the addressable patient population**.  **[1051514_cfc8f3888cf7498ea5aee260c906b7a1_0]** **[1051514_cfc8f3888cf7498ea5aee260c906b7a1_1]** 
- The company is engaged in defensive litigation with LaserOptek, anticipating significant damages and injunctive relief.  **[1051514_cfc8f3888cf7498ea5aee260c906b7a1_0]**